Open Access

The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis

Orphanet Journal of Rare Diseases20138:153

https://doi.org/10.1186/1750-1172-8-153

Received: 2 August 2013

Accepted: 12 September 2013

Published: 30 September 2013

Abstract

In 1963, five cases of alpha1-antitrypsin deficiency were reported in the scientific literature, as well as an attempt to treat pulmonary alveolar proteinosis by a massive washing of the lung (whole lung lavage). Now, fifty years later, it seems the ideal moment not only to commemorate these publications, but also to point out the influence both papers had in the following decades and how knowledge on these two fascinating rare respiratory disorders progressed over the years. This paper is therefore not aimed at being a comprehensive review for both disorders, but rather at comparing the evolution of alpha1-antitrypsin, a rare disorder, with that of pulmonary alveolar proteinosis, an ultra-rare disease. We wanted to emphasize how all stakeholders might contribute to the dissemination of the awareness of rare diseases, that need to be chaperoned from the ghetto of neglected disorders to the dignity of recognizable and treatable disorders.

Keywords

Alpha1-proteinase inhibitorPulmonary emphysemaWhole lung lavage

Introduction

In 1963 the world was in a state of fermentation, which eventually exploded in the second half of the sixties on both sides of the Atlantic Ocean and in different areas: affecting social life, the arts and protest movements. See Additional file 1 for a historic landscape. The world of Science in the meantime was thrilled by the first human organ transplants for liver, lung, and kidney. Two much less thrilling articles, but which had a great impact in the following years, were published in 1963. Carl- Bertil Laurell (Figure 1) and Sten Eriksson at the Malmö University in Sweden reported on five cases of serum alpha1-antitrypsin (AAT) absence in the electrophoresis; interestingly three out the five carriers suffered from pulmonary emphysema [1, 2]. Almost simultaneously, three physicians from the Johns Hopkins University, led by Jose Ramirez-Rivera, (Figure 2) experimented with the segmental flooding technique by means of an endobronchial catheter [3] to remove the accumulated material within the airspaces in a young male affected by pulmonary alveolar proteinosis, a mysterious disease which was first described five years earlier by Rosen and colleagues [4]. At the moment of publication, neither paper was enthusiastically acclaimed, but now fifty years after their original release it seems the ideal moment not only celebrate their publication, but most of all point out the influence both papers had in the following decades and how knowledge on these two fascinating rare respiratory disorders progressed over the years.
Figure 1

Carl-Bertil Laurell (Courtesy of eALTA Grifols).

Figure 2

José Ramirez Rivera with a young pulmonary staff member at University of Puerto Rico, 2012.

From sixties to eighties

The ten years following this discovery were marked with events of a lifetime for alpha1-antitrypsin deficiency (AATD) in Sweden. In his captivating review [5], Robin Carrell told how the original description of Laurell & Eriksson promoted an extraordinary, lively and productive environment in Sweden, and in Malmö in particular. Kjell Ohlsson, Jan Olof Jeppson, Magne Fagerhöl and Diane Cox, the latter arriving in Malmö from Norway and Canada, respectively, focused their work on the explanation of the complex electrophoretic heterogeneity of AAT, eventually contributing to the development of Pi nomenclature for AAT variants [68]. In the meantime, Christeer Larson provided evidence for the interaction of smoking with AATD [9], thus contributing to the current oxidation stress/proteinase imbalance hypothesis of the pathogenesis of emphysema, and Tomas Sveger performed the Swedish newborn national screening for AATD, a hallmark event in the epidemiology of the disorder [10]. To complete the Scandinavian perspective, the same investigators detected the inclusion of AAT within hepatocytes of AATD subjects with liver disease [11], a finding that was however anticipated a few years before by Dr Sharp and colleagues in the US [12].

The next decade was equally productive for AATD research. On the one hand, the reactive site of AAT was identified, as well as its vulnerability to oxidant stress [13, 14]. On the other hand, the crystallographic structure of AAT was elucidated and the first hypothesis was proposed that AATD was due to a structural perturbation hampering the extracellular secretion of the mature protein [15, 16]. From the molecular perspective, the mid-eighties were marked by successful cloning and sequencing of the human AAT gene (currently named SERPINA1), and the identification of the point mutation underlying the AATD Z variant [17, 18]. In the meantime, reports of longitudinal studies progressively improved our knowledge on the natural history and clinical phenotypes of individuals with AATD-associated clinical conditions [19]. The decade ended with the hallmark study on the feasibility of purified protein replacement therapy in AATD deficiency subjects [20].

The two decades following the original whole lung lavage (WLL) description were not so eventful. The major advance achieved during this period, as reported by Seymour and Presneill in their review [21], was the progressive improvement of the original washing technique described by Ramirez-Rivera, which matured into the WLL as we know it today [22]: the adoption of general anesthesia, the progressive increase of fluid volume, the usefulness of chest percussion, ending with the successful lavage of both lungs in the same session. Most papers published in this period were anecdotal studies of the disorder, they did however contribute to the expansion of our knowledge. Interestingly, some of these reports, although not directly addressing the pathogenesis of PAP, pointed to some aspects of the disease heterogeneity and development. The induction of proteinosis in the animal model of silica exposure [23], and the report on PAP occurrence in a subjects with heavy exposure to aluminum dust [24], as well as the report on rare cases of PAP in patients with hematological malignant disease [25] foresaw some of the forms of secondary PAP. The report on familial clustering of cases of PAP [26] described the occurrence of hereditary proteinosis, whereas the presence of newborn PAP as a cause of neonatal respiratory distress syndrome [27] first reported the so called PAP-like forms due to surfactant protein genetic abnormalities. Pathogenesis of the most common form of PAP, referred to as idiopathic, was unknown at that time, and bound to remain so for several decades, but David W Golde in 1976 focused his attention on the defective activity of lipid-laden macrophages [28], a cell that eventually was recognized to play a pivotal role in the development of PAP. In their paper published in 1984, William Claypool and colleagues [29] reviewed the current status of knowledge on pathogenesis and management of PAP: they carefully described their experience with 34 PAP patients, the single lung, whole lavage technique, and reviewed possible steps in PAP pathogenesis, concluding that the pathophysiology of surfactant disorders such as PAP would challenge scientists and physicians in the future: this held true for at least 10 more years.

The next twenty years : form nineties to 2010

Progress in the study of AATD from 1990 to 2010 proceeded in different directions. The AATD disease mechanism underwent progressive clarification. The most frequent AAT variant associated with severe deficiency, Glu342Lys, also referred to as PI*Z, was shown to form polymers and accumulate within hepatocytes [30], causing the deficiency in the bloodstream. This led to the hypothesis of a divergent mechanism for lung and liver disease in AATD: a deficiency mechanism (“loss-of-function”) in lung disease, and an add-on, related to the misfolding of the protein (“gain-of-function”), a conformational mechanism in liver disease [31, 32]. This Manichean view was however complicated by evidence that PI*Z polymers may also be detected and likely produced within the lung [33], thus suggesting that the add-on mechanism could also contribute to lung disease. A large series of AATD patients were studied in the United States and United Kingdom during this period, and greatly contributed to our knowledge on the clinical presentation and natural history of lung disease associated with AATD, in terms of mortality, FEV1 decline, and exacerbations [3436], as well as the associated liver disease [37]. The epidemiology of AATD received great attention after the publication of the worldwide analysis by Fredrick de Serres: in his estimation, albeit in part refined in numerous subsequent publications, ca. 30,000,000 individuals are at risk for adverse health effects due to different AATD genotypes [38]. Replacement therapy with i.v. infusion of purified human plasma protein was licensed in the last decade of the Twentieth Century, and progressively became available. As a result, thousands of patients with lung disease associated with AATD have been safely treated [39, 40]: a meta-analysis of observational studies confirmed efficacy with the decreasing decline of lung function in treated patients with an initial FEV1 between 30 and 65% predicted [41]. A number of alternative treatments for AATD have been proposed, ranging from inhalation therapy to recombinant and transgenic AAT, from gene therapy to regenerative medicine [4245]: none of these options has so far gone beyond the experimental stage. AATD played a critical role in the last two decades in building one of the most long-lived and respected hypotheses for the development of common pulmonary emphysema: the theory of an imbalance between proteinases and proteinase inhibitors, took shape, which evolved over the years, with the biochemical evidence of emphysema in subjects lacking AAT [46].

At the beginning of the last 1990’s, compared with AATD, PAP lagged behind in terms of knowledge on pathogenesis. But it quickly made up for lost time: in 1994 two papers demonstrated simultaneously and serendipitously that mice lacking GM-CSF (granulocyte-macrophage colony-stimulating factor) developed a lung disease similar to human PAP [47, 48]. These data showed that GM-CSF is critical for surfactant homeostasis in the lung, leading to subsequent studies and evidence that PAP was related to impaired surfactant catabolism by alveolar macrophages [49]. However the etiology of surfactant impairment in PAP remained unexplained until 1999, when Koh Nakata and coworkers demonstrated the presence of polyclonal, neutralizing anti-GM-CSF autoantibodies (GMAbs) in patients with “idiopathic” PAP [50]. Shortly thereafter, the pathogenesis of PAP in GM-CSF-deficient mice was elucidated in a study demonstrating that pulmonary GM-CSF is required for the terminal differentiation of alveolar macrophages [51]. Subsequently, passive transfer studies in non-human primates injected with purified human PAP patient-derived GMAbs provided proof of their role in pathogenesis of PAP in humans (and of the critical role of GM-CSF in terminal differentiation of alveolar macrophages in primates) [52]. These and other studies helped to define the previously designated “idiopathic” PAP as an autoimmune disorder and led to a new classification of surfactant disorders, including secondary PAP and rare forms of hereditary PAP [53]. The progressive evolution and improvements in the WLL technique over the years dramatically changed the natural course of the disease, which was originally charged with a mortality of approximately 30%, it progressively became a disease with a substantially favorable prognosis [21]. In the 70% of PAP patients a single WLL is enough to provide a prolonged period free of disease and/or symptoms [54]. Although WLL is a relatively safe procedure in experienced hands, it is however an invasive procedure, not exempt from severe complications. Therefore based on novel pathogenesis insights, novel therapeutic options have sprung [55]. To restore appropriate GM-CSF signaling, impaired by the presence of GMAbs, supplementation with exogenous recombinant GM-CSF has been proposed, first by subcutaneous injection, and then by inhalation [56, 57]; results were substantially better with the latter delivery method. Considering the mechanisms underlying the autoimmune form of PAP, a biological approach seemed reasonable. An open-label trial investigating Rituximab treatment which depletes the CD20 B-cell population provided intriguing, preliminary results [58].

Achievements in the first fifty years and expectations for the future

As with any anniversary, retrospection and introspection are in order. We should address the basic question: what contributions have been made during these 50 years to our understanding and management of these two rare respiratory diseases (Figure 3). The answer is largely positive, although with understandable differences:
Figure 3

Milestones of the fifty years progress in the knowledge of AATD and PAP.

  • AATD and PAP are both rare respiratory disorders, but with remarkable differences in prevalence, now recognized at: 33/100,000 for AATD and 0.7/1100.000 for PAP [59, 60]. PAP thus ranks among ultra-rare diseases (i.e. rare disease with a prevalence < 1/100,000 individuals).

  • In spite of this difference, although a formal registry for PAP is not available, published data for more than 1,000 PAP patients are available [61]. On the other hand, two large registries for AATD are active, one in the US (Alpha-1 Research Registry), and the second is an international registry (Alpha One International Registry, AIR) [62], with about a total of 9,500 AATD patients enrolled. Such a large series of patients will contribute to a better understanding of the natural history of both diseases.

  • A marked difference is however evident in molecular epidemiology data, since we have a comprehensive view for AATD [63], whereas PAP data are scattered and incomplete.

  • Large diagnostic programs for AATD have been established over the last two decades in Western countries [64], with consolidated diagnostic flow-charts for genetic testing, and new programs are currently going to be implemented in Eastern Europe, whereas for PAP we are at the early stage of establishment of reference centers in the US and Europe. However we are at a satisfactory stage, compared with the very recent past.

  • Powerful patient-advocacy groups for AATD are active both in the US [65] and Europe, whereas a PAP patient organization is present only in the US [66] and its activity is very limited.

  • Thousands of AATD patients are currently on replacement therapy in both the Americas and in Europe; in contrast, WLL is not a standardized procedure, and is available only in selected centers. A worldwide census of centers with experience performing WLL [67] hopefully will represent the first step toward standardizing the procedure.

  • Last, but not least: the search for surrogate markers to prove efficacy of replacement therapy in AATD, has greatly contributed to the development of computed tomography-based lung densitometry [6870], a technique likely to be implemented in common emphysema [71] for testing new potentially active drugs.

Major review articles are available for both disorders: at least three for AATD, covering different aspects of the disease [7275], and one for PAP (75).

On a final note, we would like to express our expectations for the coming years. The AATD community is anxiously waiting for unbiased proof of efficacy for replacement therapy and, in turn, an alignment in accessibility to therapy among European countries. Research will hopefully address alternatives to plasma purification of AAT, in order to improve efficacy, reduce costs, and broaden availability: inhalation delivery, recombinant AAT, as well as regenerative medicine, and drugs able to correct misfolded AAT are all under active investigation, as stated above. On the other hand, it is desirable that detection programs reduce the huge gap between diagnosed and estimated individuals with severe AATD, making epidemiology data more robust. The path for PAP is understandably longer, but hopefully not winding. Registries, standards of care, networks/centers of excellence, precise epidemiology (does ultra-rare status stem from ignorance?), patient advocacy for PAP are still in the embryonic stage. Lessons from AATD should be extended to PAP, with the hope that it will share the same interest as AATD: biological treatments will hopefully help achieve this goal. This would definitely bring PAP out of the ghetto of neglected diseases, bringing it the parallel with AATD, converging into the dignity of rare diseases with equal awareness. It is hoped that such a process does not require fifty more years.

Declarations

Acknowledgments

The authors are deeply grateful to their coworkers in Cincinnati and Pavia, respectively, for their continuing dedication over the years in the management, and assessment of patients with AATD and PAP, and for the enthusiasm, and skillfulness poured in the translational research for these two rare respiratory disorders. This paper has been in part supported by the Italian Agency for Medicines (AIFA) project for Independent Research 2007 (FARM7MCPK4), from E-Rare Project 2009 (EuPAPNet), from the Scientific Direction of the San Matteo Hospital Foundation of Pavia, and from an unrestricted grant from Grifols Inc.

Authors’ Affiliations

(1)
Cincinnati Children Hospital Medical Center
(2)
Department of Molecular Medicine, Pneumology Unit, San Matteo Hospital Foundation, University of Pavia

References

  1. Laurell C-B, Eriksson S: The electrophoretic α1- globulin pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963, 15: 132-140.View ArticleGoogle Scholar
  2. Eriksson S, Laurell C-B: A new abnormal serum globulin alpha-1 antitrypsin. Acta Chem Scand. 1963, 17: 150-153.View ArticleGoogle Scholar
  3. Ramirez RJ, Schultz RB, Dutton RE: Pulmonary alveolar proteinosis. A new technique and rationale for treatment. Arch Int Med. 1963, 112: 173-185. 10.1001/archinte.1963.03860020071008.View ArticleGoogle Scholar
  4. Rosen SH, Castelman B, Liebow AA: Pulmonary alveolar proteinosis. N Engl J Med. 1958, 258: 1123-1142. 10.1056/NEJM195806052582301.PubMedView ArticleGoogle Scholar
  5. Carrell RW: What we owe to α1- antitrypsin and to Carl-Bertil Laurell. COPD. 2004, 1: 71-84. 10.1081/COPD-120028703.PubMedView ArticleGoogle Scholar
  6. Fagerhol MK, Laurell C-B: The polymorphism of prealbumins’ and α1-antitrypsin in human sera. Clin Chim Acta. 1967, 16: 199-203. 10.1016/0009-8981(67)90181-7.PubMedView ArticleGoogle Scholar
  7. Fagerhol MK: The Pi system. Genetic variants of α1-antitrypsin. Ser Haematol. 1968, 1: 153-161.Google Scholar
  8. Cox DW: New variants of α1-antitrypsin: comparison of Pi phenotypng techniques. Am J Hum Genet. 1981, 33: 354-365.PubMed CentralPubMedGoogle Scholar
  9. Larsson C: Natural history and life expectancy in severe alpha1-antitrypsin deficiency, PiZ. Acta Med Scand. 1978, 204: 345-351.PubMedView ArticleGoogle Scholar
  10. Sveger T: Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Eng J Med. 1976, 294: 1316-1321. 10.1056/NEJM197606102942404.View ArticleGoogle Scholar
  11. Jeppsson J-O, Larsson C, Eriksson S: Characterization of α1-antitrypsin in the inclusion bodies from the liver in α1-antitrypsin deficiency. N Engl J Med. 1975, 293: 576-579. 10.1056/NEJM197509182931203.PubMedView ArticleGoogle Scholar
  12. Sharp HL, Bridges RA, Krivit W, Freier EF: Cirrhosis associated with alpha-1 antitrypsin deficiency: a previously unrecognized and inherited disorder. J Lab Clin Med. 1969, 73: 934-939.PubMedGoogle Scholar
  13. Johnson D, Travis J: Structural evidence for methionine at the reactive site of human a-1- proteinase inhibitor. J Biol Chem. 1978, 253: 7142-7144.PubMedGoogle Scholar
  14. Johnson D, Travis J: The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem. 1979, 254: 4022-4026.PubMedGoogle Scholar
  15. Carrell RW: a1-antitrypsin: molecular pathology, leukocytes and tissue damage. J Clin Invest. 1986, 78: 1427-1431. 10.1172/JCI112731.PubMed CentralPubMedView ArticleGoogle Scholar
  16. Loebermann H, Tokuoka R, Deisenhofer J, Huber R: Human α1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984, 177: 531-556. 10.1016/0022-2836(84)90298-5.PubMedView ArticleGoogle Scholar
  17. Long GL, Chandra I, Woo SLC, Davie EW, Kurachi K: Complete sequence of the cDNA for human α1-antitrypsin and the gene for the S variant. Biochemistry. 1984, 23: 4828-4837. 10.1021/bi00316a003.PubMedView ArticleGoogle Scholar
  18. Nukiwa T, Satoh K, Brantly ML, Ogushi F, Fells GA, Courtney M, Crystal RG: Identification of a second mutation in the protein coding sequence of the Z-type alpha1-antitrypsin gene. J Biol Chem. 1986, 261: 15989-15994.PubMedGoogle Scholar
  19. Buist AS, Burrows B, Eriksson S, Mittman C, Wu M: The natural history of air-flow obstruction in PiZ emphysema. Report of an NHLBI Workshop. Am Rev Respir Dis. 1983, 127 (suppl): 43-45.Google Scholar
  20. Wewers MD, Casolaro MA, Sellers S, Swayze SC, McPhaul KM, Crystal RG: Replacement therapy for alpha1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987, 316: 1055-1062. 10.1056/NEJM198704233161704.PubMedView ArticleGoogle Scholar
  21. Seymour JF, Presneill JJ: Pulmonary alveolar proteinosis. Progress in the first 44 years. Am J Respir Crit Care Med. 2002, 166: 215-235. 10.1164/rccm.2109105.PubMedView ArticleGoogle Scholar
  22. Ramirez J, Kieffer RF, Ball WC: Bronchopulmonary lavage in man. Ann Intern Med. 1965, 63: 819-828. 10.7326/0003-4819-63-5-819.PubMedView ArticleGoogle Scholar
  23. Happleston AG: Animal model of human disease. Pulmonary alveolar lipo-proteinosis. Animal model : silica – induced pulmonary alveolar lipo-proteinosis. Am J Pathol. 1975, 78: 171-174.Google Scholar
  24. Miller RR, Churg AM, Hutcheon M, Lom S: Pulmonary alveolar proteinosis and aluminium dust exposure. Am Rev Respir Dis. 1984, 130: 312-315.PubMedGoogle Scholar
  25. Bedrossian CW, Luna MA, Conklin RH, Miller WC: Alveolar proteinosis as a consequence of immunosuppression. A hypothesis based on clinical and pathologic observations. Hum Pathol. 1980, 11 (Suppl 5): 527-535.PubMedGoogle Scholar
  26. Teja K, Cooper PH, Squires JE, Schanatterly PT: Pulmonary alveolar proteinosis in four siblings. M Engl J Med. 1981, 305: 1390-1392. 10.1056/NEJM198112033052305.View ArticleGoogle Scholar
  27. Coleman M, Dehler LP, Sibley RK, Burke BA, l’Heureux PR, Thompson TR: Pulmonary alveolar proteinosis : an uncommon cause of chronic neonatal respiratory distress. Am Rev Respir Dis. 1980, 121: 583-586.PubMedView ArticleGoogle Scholar
  28. Golde DW, Territo M, Finley TN, Cline MJ: Defective lung macrophages in pulmonary alveolar proteinosis. Ann Intern Med. 1976, 85: 304-309. 10.7326/0003-4819-85-3-304.PubMedView ArticleGoogle Scholar
  29. Claypool WD, Rogers RM, Matuschak GM: Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis). Chest. 1984, 85: 550-558. 10.1378/chest.85.4.550.PubMedView ArticleGoogle Scholar
  30. Lomas DA, Evans DL, Finch JT, Carrell RW: The mechanism of Z α1-antitrypsin accumulation in the liver. Nature. 1992, 357: 605-607. 10.1038/357605a0.PubMedView ArticleGoogle Scholar
  31. Le A, Graham KS, Sifers RN: Intracellular degradation of the transport-impaired human PiZ α1-antitrypsin variant. Biochemical mapping of the degradative event among compartments in the secretory pathway. J Biol Chem. 1990, 265: 14001-14007.PubMedGoogle Scholar
  32. Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH: A lag in intracellular degradation of mutant α1-antitrypsin correlates with liver disease phenotype in homozygous PiZZ α1-antitrypsin deficiency. PNAS. 1994, 91: 9014-9018. 10.1073/pnas.91.19.9014.PubMed CentralPubMedView ArticleGoogle Scholar
  33. Gooptu B, Lomas DA: Polymers and inflammation : disease mechanisms of the serpinopathies. J Exp Med. 2008, 205: 1529-1534. 10.1084/jem.20072080.PubMed CentralPubMedView ArticleGoogle Scholar
  34. The Alpha-1-Antitrypsin Deficiency Registry Study Group: Survival and FEV1 decline in individuals with severe deficiency of alpha1- antitrypsin. Am J Respir Crit Care Med. 1998, 158: 49-59.View ArticleGoogle Scholar
  35. Dowson LJ, Guest PJ, Stockley RA: Longitudinal changes in physiological, radiological, and health status measurements in alpha (1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 2001, 164: 1805-1809. 10.1164/ajrccm.164.10.2106036.PubMedView ArticleGoogle Scholar
  36. Needham M, Stockley RA: Exacerbations in alpha (1)-antitrypsin deficiency. Eur Respir J. 2005, 25: 992-1000. 10.1183/09031936.05.00074704.PubMedView ArticleGoogle Scholar
  37. Dawwas MF, Davies SE, Griffths WJH, Lomas DA, Alexander GJ: Prevalence and risk factors for liver involvement in individuals with PIZZ-related lung disease. Am J Respir Crit Care Med. 2013, 187: 502-508. 10.1164/rccm.201204-0739OC.PubMedView ArticleGoogle Scholar
  38. De Serres FJ: Worldwide racial and ethnic distribution of α1-antitrypsin deficiency. Chest. 2002, 122: 1818-1829. 10.1378/chest.122.5.1818.PubMedView ArticleGoogle Scholar
  39. Habusriwil H, Stockley RA: Alpha1-antitrypsin replacement therapy: current status. Curr Opin Pulm Med. 2006, 12: 125-131. 10.1097/01.mcp.0000208452.57854.c6.View ArticleGoogle Scholar
  40. Tonelli AR, Brantly ML: Augmentation therapy in alpha1-antitrypsin deficiency: advances and controversies. Ther Adv Respir Dis. 2010, 4: 289-312. 10.1177/1753465810373911.PubMedView ArticleGoogle Scholar
  41. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navicks RJ: Augmentation therapy for a1-antitrypsin deficiency : a meta-analysis. COPD. 2009, 6: 177-184. 10.1080/15412550902905961.PubMedView ArticleGoogle Scholar
  42. Luisetti M, Travis J: Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor. Chest. 1996, 110: 278S-283S. 10.1378/chest.110.6_Supplement.278S.PubMedView ArticleGoogle Scholar
  43. Sandhaus RA: New and emerging therapies for alpha1-antitrypsin deficiency. Thorax. 2004, 59: 904-909. 10.1136/thx.2003.006551.PubMed CentralPubMedView ArticleGoogle Scholar
  44. Flotte TR, Mueller C: Gene therapy for alpha1-antitrypsin deficiency. Hum Mol Genet. 2011, 20: R87-R92. 10.1093/hmg/ddr156.PubMed CentralPubMedView ArticleGoogle Scholar
  45. Wilson AA, Kwok LW, Hovav AH, Ohle SJ, Little FF, Fine A, Kotton DN: Sustained expression of α1-antitrypsin after transplantation of manipulated hematopoietic stem cells. Am J Respir Cell Mol Biol. 2008, 39: 133-141. 10.1165/rcmb.2007-0133OC.PubMed CentralPubMedView ArticleGoogle Scholar
  46. Snider GL: Emphysema: the first two centuries--and beyond. A historical overview, with suggestions for future research: Part 1 & 2. Am Rev Respir Dis. 1992, 146: 1334-1344. 10.1164/ajrccm/146.5_Pt_1.1334. 1615-1622.PubMedView ArticleGoogle Scholar
  47. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, Maher DW, Cebon J, Sinickas V, Dunn ER: Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pethology. Proc Natl Acad Sci USA. 1994, 91: 5592-5596. 10.1073/pnas.91.12.5592.PubMed CentralPubMedView ArticleGoogle Scholar
  48. Dranoff G, Crawford AD, Sedelain M, Ream B, Rashid A, Bronson RT, Dickersin GR, Bachurski CJ, Mark EL, Whitsett JA: Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994, 264: 713-716. 10.1126/science.8171324.PubMedView ArticleGoogle Scholar
  49. Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA: Pulmonary epithelial expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest. 1996, 97: 649-655. 10.1172/JCI118461.PubMed CentralPubMedView ArticleGoogle Scholar
  50. Kitamura T, Tanaka N, Watanabe J, Uchida J, Kanegasaki S, Yamada Y, Nakata K: Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/ macrophage colony-stimulating factor. J Exp Med. 1999, 190: 875-880. 10.1084/jem.190.6.875.PubMed CentralPubMedView ArticleGoogle Scholar
  51. Shibata Y, Berclaz P-Y, Chroneos ZC, Whitsett JA, Trapnell BC: GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 2001, 15: 557-567. 10.1016/S1074-7613(01)00218-7.PubMedView ArticleGoogle Scholar
  52. Sakagami T, Uchida K, Suzuki T, Carey BC, Wood RE, Wert SE, Whitsett JA, Trapnell BC, Luisetti M: Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med. 2009, 361: 2679-2681. 10.1056/NEJMc0904077.PubMed CentralPubMedView ArticleGoogle Scholar
  53. Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, Luisetti M, Wert SE, Rubin BK, Kevill K, Chalk C, Whitsett JA, Stevens C, Nogee LM, Campo I, Trapnell BC: Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010, 182: 1292-1304. 10.1164/rccm.201002-0271OC.PubMed CentralPubMedView ArticleGoogle Scholar
  54. Beccaria M, Luisetti M, Rodi G, Corsico A, Zoia MC, Colato S, Pochetti P, Braschi A, Pozzi E, Cerveri I: Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J. 2004, 23: 526-531. 10.1183/09031936.04.00102704.PubMedView ArticleGoogle Scholar
  55. Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC: Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis. 2010, 4: 239-248. 10.1177/1753465810378023.PubMedView ArticleGoogle Scholar
  56. Seymour JF, Presneill JJ, Schoch OD, Downie GH, Moore PE, Doyle IR, Vincent JM, Nakata K, Kitamura T, Langton D, Pain MC, Dunn AR: Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001, 163: 524-531. 10.1164/ajrccm.163.2.2003146.PubMedView ArticleGoogle Scholar
  57. Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ishii H, Yokoba M, Tanaka N, Yamaguchi E, Tsuchiashi N, Morimoto K, Akira M, Terada M, Otsuka J, Ebina M, Kaneko C, Nukiwa T, Krischer JP, Akazawa K, Nakata K: Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010, 181: 1345-1354. 10.1164/rccm.200906-0978OC.PubMed CentralPubMedView ArticleGoogle Scholar
  58. Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, Dalrymple H, Karnekar R, Thomassen MJ: An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J. 2011, 38: 1361-1367. 10.1183/09031936.00197710.PubMedView ArticleGoogle Scholar
  59. Orphanet Report Series: Prevalence of rare diseases : bibliographic data. June 2013. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf.Google Scholar
  60. Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara W, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsushihashi O, Kaneko C, Nukiwa T, Sakatani N, Krischer JP, Nakata K, for the Japanese Center for the Lung Lung Disease Consortium: Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008, 177: 752-762. 10.1164/rccm.200708-1271OC.PubMed CentralPubMedView ArticleGoogle Scholar
  61. Campo I, Mariani F, Rodi G, Paracchini E, Tsana E, Piloni D, Nobili I, Kadija Z, Corsico A, Cerveri I, Chalk C, Trapnell BC, Braschi A, Tinelli C, Luisetti M: Assessment and management of pulmonary alveolar proteinosis in a reference center. Orphanet J Rare Dis. 2013, 8: 40. 10.1186/1750-1172-8-40.PubMed CentralPubMedView ArticleGoogle Scholar
  62. Stockley RA, Luisetti M, Miravitlles M, Piituilanen E, Fernandez P, on behalf of the Alpha One International Registry (AIR): Ongoing reserach in Europe: Alpha One International Registry (AIR) objective and development. Eur Respir J. 2007, 29: 582-586. 10.1183/09031936.00053606.PubMedView ArticleGoogle Scholar
  63. Blanco I, de Serres FJ, Cárcaba V, Lara B, Fernández-Bustillo E: Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method. Hepat Mon. 2012, 12: e7434.PubMed CentralPubMedView ArticleGoogle Scholar
  64. Miravitlles M, Herr C, Ferrarotti I, Jardi R, Rodriguez-Frias F, Luisetti M, Bals R: Laboratory testing of individuals with severe α1-antitrypsin deficiency in three European Centres. Eur Respir J. 2010, 35: 960-968. 10.1183/09031936.00069709.PubMedView ArticleGoogle Scholar
  65. Walsh JW, Snider GL, Stoller JK: A review of the Alpha-1 Foundation : its formation, impact, and critical success factors. Respir Care. 2006, 51: 526-531.PubMedGoogle Scholar
  66. Pulmonary Alveolar Proteinosis Foundation:http://www.papfoundation.org/home.html.
  67. Luisetti M: Call for an International survey on therapeutic lavage for pulmonary alveolar proteinosis. Eur Respir J. 2012, 39: 1049. 10.1183/09031936.00226311.PubMedView ArticleGoogle Scholar
  68. Dirksen A, Dijkam JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Hecksher T, Viskum K, Stolk J: A randomized clinical trial of α1-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999, 160: 1468-1472. 10.1164/ajrccm.160.5.9901055.PubMedView ArticleGoogle Scholar
  69. Parr DG, Stoel BC, Stolk J, Stockely RA: Pattern of emphysema distribution in α1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004, 170: 1172-1178. 10.1164/rccm.200406-761OC.PubMedView ArticleGoogle Scholar
  70. Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A: Therapeutic efficacy of alpha1-antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of two randomized clinical trials using computed tomography densitometry. Respir Res. 2010, 11: 36. 10.1186/1465-9921-11-36.View ArticleGoogle Scholar
  71. Coxson HO, Diksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverly PMA, Celli B, Crim C, Duvoix A, Nasute Fauerback P, Lomas DA, MacNee W, Mayer RJ, Miller BE, Muller NL, Rennard SI, Silverman EK, Tal-Singer R, Wouters EFM, Vestbo J, for ECLIPSE Investigators: The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis form the ECLIPSE study. Lancet Respir Med. 2013, 1: 129-136. 10.1016/S2213-2600(13)70006-7.PubMedView ArticleGoogle Scholar
  72. Carrell RW, Lomas DA: Alpha1antitrypsin deficiency. A model for conformational diseases. N Engl J Med. 2002, 346: 45-53. 10.1056/NEJMra010772.PubMedView ArticleGoogle Scholar
  73. Stoller JK, Aboussouan LS: α1-antitrypsin deficiency. Lancet. 2005, 365: 2225-2236. 10.1016/S0140-6736(05)66781-5.PubMedView ArticleGoogle Scholar
  74. Silverman EJ, Sandhaus RA: Alpha1 antitrypsin deficiency. N Engl J Med. 2009, 360: 2749-2757. 10.1056/NEJMcp0900449.PubMedView ArticleGoogle Scholar
  75. Trapnell BC, Whitsett JA, Nakata K: Pulmonary alveolar proteinosis. N Engl J Med. 2003, 349: 2527-2539. 10.1056/NEJMra023226.PubMedView ArticleGoogle Scholar

Copyright

© Trapnell and Luisetti; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement